Abstract
BackgroundAutoimmune diseases (ADs) affect more than 24 million people in the United States. Although patients with AD are usually excluded from ICI clinical trials, real world evidence suggests ICIs are...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
